NeuroVera Review: Six Ingredients, Uneven Dose Transparency

NeuroVera gives six ingredient weights, but not six equally interpretable doses. Its Bacopa extract lacks a stated bacoside percentage, lion’s mane is listed as fruiting-body powder, and the DHA line carries a 10% designation. This review asks what those disclosures let a buyer compare—and what the six-ingredient presentation leaves unresolved.

Affiliate disclosure: Planet Wellness Report may earn a commission from qualifying purchases through links on this page. This review assesses product facts and research independently; we have not personally tested NeuroVera, and no numerical product rating is assigned.

Six weights do not make six evidence matches

The official panel rechecked on October 19, 2026 specifies two capsules and 30 servings per bottle. The manufacturer positions it for memory, focus, and “neural activation.” That narrative is a commercial claim, not a measured outcome of this current formula. [1]

The capsule format is a factual feature. Its usefulness depends on wanting these exact ingredients together, not merely wanting fewer bottles. Someone seeking a standardized Bacopa extract, a clearly quantified active DHA intake, or assessment of worsening memory has a different priority.

The current formula, as the official label lists it

Per two-capsule serving: lion’s mane fruiting-body mushroom powder 500 mg; schisandra fruit extract 10:1 250 mg; gotu kola whole-herb powder 200 mg; Bacopa monnieri whole-herb extract 100 mg; shilajit extract 75 mg, standardized to 40% fulvic acid; and “DHA (Docosahexaenoic Acid) 10%” 25 mg. We preserve the DHA label wording rather than assuming it represents 25 mg of active DHA.

Other ingredients are HPMC (vegetable capsule), magnesium stearate, olive oil, and silicon dioxide. The formula is not presented as an undisclosed proprietary blend. However, the Bacopa entry does not state bacoside standardization, and a powder, an extract ratio, and a standardized constituent are different descriptions. Milligram totals alone cannot establish equivalence to a clinical preparation.

Bacopa: relevant memory research, with mixed findings

Bacopa is one of the more clinically studied ingredients here. A 2012 systematic review of six randomized trials in adults without dementia found the clearest signal for memory free recall; evidence for other cognitive domains was less consistent. Studies used particular extracts, typically 300–450 mg daily over 12 weeks. That is useful ingredient-level evidence, not a universal improvement in every aspect of thinking. [4]

A 2025 trial adds balance: 101 adults aged 40–70 with subjective memory and attention problems were randomized to 300 mg daily of Bacumen or placebo. Among 87 completers, the primary verbal-learning, attention, and working-memory outcomes did not improve more with Bacopa. Secondary stress and task-related fatigue measures showed benefits, while digestive complaints and headaches were more frequent. NeuroVera’s 100 mg entry is a different, incompletely characterized extract; neither a matching effect nor no effect can be inferred simply from the milligrams. [5]

Lion’s mane: promising, early human evidence

Lion’s mane is interesting because experimental work concerns nerve-related pathways, and small human studies have examined cognition. A 2023 pilot randomized 41 healthy young adults to 1.8 g daily or placebo for 28 days. Findings included faster performance on one task after an acute dose and a trend toward less subjective stress, rather than a broad, established memory benefit. [6]

The evidence is preliminary and depends on the preparation, population, and outcome. NeuroVera lists 500 mg of fruiting-body powder, which is not the same intervention as the pilot’s 1.8 g preparation. A mechanistic rationale makes the ingredient worth studying, but does not demonstrate new nerve growth or a cognitive improvement in a customer using this formula. [6]

Gotu kola: limited cognitive evidence

Gotu kola has a traditional cognitive-support rationale. A 2017 systematic review and meta-analysis did not find significant improvement over comparators in the assessed cognitive domains. Small samples, varied preparations, and incomplete standardization limited interpretation. Some mood findings were more favorable, but mood and memory are distinct outcomes. The label’s 200 mg whole-herb powder cannot be assumed equivalent to extracts studied elsewhere. [7]

Schisandra and shilajit: stronger rationale than human proof

Schisandra supplies lignans studied in oxidative-stress and nerve-related models. A review of these compounds describes predominantly experimental evidence. That gives a formulation rationale, while direct human evidence for everyday memory or focus remains limited. NeuroVera lists a 10:1 fruit extract; that ratio alone does not specify its lignan content or establish clinical equivalence. [8]

Shilajit is a complex material containing fulvic substances. A review exploring its possible cognitive role discussed mechanistic and preclinical findings and the need for human investigation. NeuroVera discloses a 40% fulvic-acid standardization, a useful identity detail. It does not establish that 75 mg improves memory. Evidence from studies of other outcomes, such as physical performance, would not answer that cognitive question. [9]

DHA: important biology, a different supplementation question

DHA is an omega-3 fatty acid present in brain-cell membranes. NIH’s Office of Dietary Supplements describes mixed cognitive supplementation research, including trials without cognitive benefit. Observational associations with dietary intake cannot establish that adding a supplement improves memory. NeuroVera’s small, 10%-designated ingredient entry should not be treated as comparable to higher-dose DHA interventions or as a substitute for assessing overall omega-3 intake. [10]

Which specifications help—and where they stop

The label identifies lion’s mane fruiting body, a schisandra 10:1 extract, and shilajit standardized to 40% fulvic acid. Those details are useful for identifying materials. They are not a uniform standard of cognitive evidence: Bacopa and lion’s mane have relevant but mixed or preliminary human research, while the gotu kola review was not positive for the assessed cognitive domains. [1] [4] [6] [7]

Where expectations should stay measured

No published randomized efficacy trial of the current finished NeuroVera formula was verified in this review. The Bacopa and lion’s mane comparisons above concern different preparations and amounts. A buyer cannot infer the combined effect or a time to results by adding their ingredient findings together.

The manufacturer makes manufacturing and testing claims, but no current batch-specific certificate was available for independent assessment in the materials checked. We do not award a verified third-party-testing claim. Disclosure of capsule weights does not resolve identity, constituent strength, contaminant testing, and clinical outcome as if they were one question.

Tolerability and who should check first

Ingredient trials suggest that digestive symptoms can occur; the newer Bacopa trial also reported headaches. Stop using a supplement and seek appropriate advice if concerning reactions occur. A multi-ingredient formula deserves a medication review, especially if you take blood thinners or have an ongoing health condition. The official page advises medical consultation in these circumstances and identifies pregnancy, nursing, and use under age 18 as unsuitable contexts. [1] [5]

For shilajit, purification and contaminant control matter; the mechanistic review warns against using unprocessed material. This does not establish a contamination problem in NeuroVera. A buyer who prioritizes quality verification can ask the manufacturer for current testing documentation, alongside any relevant allergy and medication questions.

Compare one defined objective with the fixed blend

For a Bacopa-specific comparison, look for the extract identity, bacoside method, daily quantity, and study population; 100 mg of this unspecified extract cannot be assumed to match the 300–450 mg preparations in the review. For DHA, obtain clarification of the “10%” entry instead of treating it as 25 mg active DHA. A single-ingredient alternative may be easier to evaluate, but we did not verify a like-for-like market price comparison. [1] [4]

For a separate question about acute focus, our article on caffeine and L-theanine evaluates that combination. It is not the NeuroVera formula and does not supply evidence for it. Our guide to improving focus and concentration addresses routines that remain relevant whichever supplement format you consider.

A price display that needs a final-order check

At the October 19, 2026 check, the official page displayed $49 for one bottle and $39/$29 per bottle for three/six bottles, alongside $54.44 in its one-time/subscription offer selector. Those visible figures do not establish one unambiguous selected-order total. We therefore do not report a verified current cost per serving or call NeuroVera cheaper than separate products. Confirm the selected purchase mode, bottle count, total, shipping, and any renewal before paying. [1]

The refund policy advertises a 365-day window; subscription terms describe recurring charges and management through order-confirmation links. The page contains shipping offers whose conditions vary by order. Read the terms for the actual destination and selection. We did not place an order, test delivery, or request a refund. [1] [2] [3]

The main product link remains available to inspect the current offer. An affiliate commission does not resolve any of the label or price-selection questions in this review.

A capsule preference with specifications still to resolve

The strongest reason to consider NeuroVera is a deliberate preference for this exact six-ingredient capsule blend with individually listed weights. The strongest reason to skip it is a need for tightly specified trial-matched dosing: Bacopa standardization and the DHA designation remain unresolved, and some ingredients have little direct human cognitive support. Better constituent disclosure, batch documentation, or an independent controlled trial of the current formula could materially change the judgment.

It is not a substitute for assessment of persistent brain fog or worsening memory. The guides to memory habits and memory and aging address decisions that do not depend on choosing a capsule.

Editorial update, October 19, 2026: Aligned the opening, summary and purchase conclusion with preparation-specific limitations; documented conflicting offer figures without asserting a current per-serving price. This is a documentary reassessment; no personal use or clinical product test is claimed.